-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services ...
Lab is located in same building as PPD ® Laboratories’ Central Lab and will support Asia-Pacific oncology trials FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc.
NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic ...
NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial ...
Investor's Business Daily on MSN
NeoGenomics joins elite club of stocks with RS ratings over 90
NeoGenomics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. NeoGenomics met analysts’ revenue expectations last quarter, ...
FORT MYERS, Fla., December 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results